Global Non-Hodgkin's Lymphoma Drug Market 2024 by Company, Regions, Type and Application, Forecast to 2030
Page: 116
Published Date: 09 Jan 2024
Category: Pharma & Healthcare
PDF Download
Get FREE Sample
Customize Request
-
Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags
Description
According to our (Global Info Research) latest study, the global Non-Hodgkin's Lymphoma Drug market size was valued at USD 8119.4 million in 2023 and is forecast to a readjusted size of USD 12940 million by 2030 with a CAGR of 6.9% during review period.
Non-Hodgkin's lymphoma is a type of cancer that begins in your lymphatic system, which is part of the body's germ-fighting immune system. In non-Hodgkin's lymphoma, white blood cells called lymphocytes grow abnormally and can form growths (tumors) throughout the body.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
The Global Info Research report includes an overview of the development of the Non-Hodgkin's Lymphoma Drug industry chain, the market status of Hospital (Oral, Injection), Retail Pharmacy (Oral, Injection), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Non-Hodgkin's Lymphoma Drug.
Regionally, the report analyzes the Non-Hodgkin's Lymphoma Drug markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Non-Hodgkin's Lymphoma Drug market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Non-Hodgkin's Lymphoma Drug market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Non-Hodgkin's Lymphoma Drug industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Oral, Injection).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Non-Hodgkin's Lymphoma Drug market.
Regional Analysis: The report involves examining the Non-Hodgkin's Lymphoma Drug market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Non-Hodgkin's Lymphoma Drug market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Non-Hodgkin's Lymphoma Drug:
Company Analysis: Report covers individual Non-Hodgkin's Lymphoma Drug players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Non-Hodgkin's Lymphoma Drug This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hospital, Retail Pharmacy).
Technology Analysis: Report covers specific technologies relevant to Non-Hodgkin's Lymphoma Drug. It assesses the current state, advancements, and potential future developments in Non-Hodgkin's Lymphoma Drug areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Non-Hodgkin's Lymphoma Drug market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Non-Hodgkin's Lymphoma Drug market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Oral
Injection
Market segment by Application
Hospital
Retail Pharmacy
Other
Market segment by players, this report covers
Roche
Gilead Sciences
TG Therapeutics
Bayer
Secura Bio
Epizyme
Eisai
Acrotech Biopharma
Teva
Eagle Pharmaceuticals
MundiPharma
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Non-Hodgkin's Lymphoma Drug product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Non-Hodgkin's Lymphoma Drug, with revenue, gross margin and global market share of Non-Hodgkin's Lymphoma Drug from 2019 to 2024.
Chapter 3, the Non-Hodgkin's Lymphoma Drug competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Non-Hodgkin's Lymphoma Drug market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Non-Hodgkin's Lymphoma Drug.
Chapter 13, to describe Non-Hodgkin's Lymphoma Drug research findings and conclusion.
Table of Contents
1 Market Overview
1.1 Product Overview and Scope of Non-Hodgkin's Lymphoma Drug
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Non-Hodgkin's Lymphoma Drug by Type
1.3.1 Overview: Global Non-Hodgkin's Lymphoma Drug Market Size by Type: 2019 Versus 2023 Versus 2030
1.3.2 Global Non-Hodgkin's Lymphoma Drug Consumption Value Market Share by Type in 2023
1.3.3 Oral
1.3.4 Injection
1.4 Global Non-Hodgkin's Lymphoma Drug Market by Application
1.4.1 Overview: Global Non-Hodgkin's Lymphoma Drug Market Size by Application: 2019 Versus 2023 Versus 2030
1.4.2 Hospital
1.4.3 Retail Pharmacy
1.4.4 Other
1.5 Global Non-Hodgkin's Lymphoma Drug Market Size & Forecast
1.6 Global Non-Hodgkin's Lymphoma Drug Market Size and Forecast by Region
1.6.1 Global Non-Hodgkin's Lymphoma Drug Market Size by Region: 2019 VS 2023 VS 2030
1.6.2 Global Non-Hodgkin's Lymphoma Drug Market Size by Region, (2019-2030)
1.6.3 North America Non-Hodgkin's Lymphoma Drug Market Size and Prospect (2019-2030)
1.6.4 Europe Non-Hodgkin's Lymphoma Drug Market Size and Prospect (2019-2030)
1.6.5 Asia-Pacific Non-Hodgkin's Lymphoma Drug Market Size and Prospect (2019-2030)
1.6.6 South America Non-Hodgkin's Lymphoma Drug Market Size and Prospect (2019-2030)
1.6.7 Middle East and Africa Non-Hodgkin's Lymphoma Drug Market Size and Prospect (2019-2030)
2.1 Roche
2.1.1 Roche Details
2.1.2 Roche Major Business
2.1.3 Roche Non-Hodgkin's Lymphoma Drug Product and Solutions
2.1.4 Roche Non-Hodgkin's Lymphoma Drug Revenue, Gross Margin and Market Share (2019-2024)
2.1.5 Roche Recent Developments and Future Plans
2.2 Gilead Sciences
2.2.1 Gilead Sciences Details
2.2.2 Gilead Sciences Major Business
2.2.3 Gilead Sciences Non-Hodgkin's Lymphoma Drug Product and Solutions
2.2.4 Gilead Sciences Non-Hodgkin's Lymphoma Drug Revenue, Gross Margin and Market Share (2019-2024)
2.2.5 Gilead Sciences Recent Developments and Future Plans
2.3 TG Therapeutics
2.3.1 TG Therapeutics Details
2.3.2 TG Therapeutics Major Business
2.3.3 TG Therapeutics Non-Hodgkin's Lymphoma Drug Product and Solutions
2.3.4 TG Therapeutics Non-Hodgkin's Lymphoma Drug Revenue, Gross Margin and Market Share (2019-2024)
2.3.5 TG Therapeutics Recent Developments and Future Plans
2.4 Bayer
2.4.1 Bayer Details
2.4.2 Bayer Major Business
2.4.3 Bayer Non-Hodgkin's Lymphoma Drug Product and Solutions
2.4.4 Bayer Non-Hodgkin's Lymphoma Drug Revenue, Gross Margin and Market Share (2019-2024)
2.4.5 Bayer Recent Developments and Future Plans
2.5 Secura Bio
2.5.1 Secura Bio Details
2.5.2 Secura Bio Major Business
2.5.3 Secura Bio Non-Hodgkin's Lymphoma Drug Product and Solutions
2.5.4 Secura Bio Non-Hodgkin's Lymphoma Drug Revenue, Gross Margin and Market Share (2019-2024)
2.5.5 Secura Bio Recent Developments and Future Plans
2.6 Epizyme
2.6.1 Epizyme Details
2.6.2 Epizyme Major Business
2.6.3 Epizyme Non-Hodgkin's Lymphoma Drug Product and Solutions
2.6.4 Epizyme Non-Hodgkin's Lymphoma Drug Revenue, Gross Margin and Market Share (2019-2024)
2.6.5 Epizyme Recent Developments and Future Plans
2.7 Eisai
2.7.1 Eisai Details
2.7.2 Eisai Major Business
2.7.3 Eisai Non-Hodgkin's Lymphoma Drug Product and Solutions
2.7.4 Eisai Non-Hodgkin's Lymphoma Drug Revenue, Gross Margin and Market Share (2019-2024)
2.7.5 Eisai Recent Developments and Future Plans
2.8 Acrotech Biopharma
2.8.1 Acrotech Biopharma Details
2.8.2 Acrotech Biopharma Major Business
2.8.3 Acrotech Biopharma Non-Hodgkin's Lymphoma Drug Product and Solutions
2.8.4 Acrotech Biopharma Non-Hodgkin's Lymphoma Drug Revenue, Gross Margin and Market Share (2019-2024)
2.8.5 Acrotech Biopharma Recent Developments and Future Plans
2.9 Teva
2.9.1 Teva Details
2.9.2 Teva Major Business
2.9.3 Teva Non-Hodgkin's Lymphoma Drug Product and Solutions
2.9.4 Teva Non-Hodgkin's Lymphoma Drug Revenue, Gross Margin and Market Share (2019-2024)
2.9.5 Teva Recent Developments and Future Plans
2.10 Eagle Pharmaceuticals
2.10.1 Eagle Pharmaceuticals Details
2.10.2 Eagle Pharmaceuticals Major Business
2.10.3 Eagle Pharmaceuticals Non-Hodgkin's Lymphoma Drug Product and Solutions
2.10.4 Eagle Pharmaceuticals Non-Hodgkin's Lymphoma Drug Revenue, Gross Margin and Market Share (2019-2024)
2.10.5 Eagle Pharmaceuticals Recent Developments and Future Plans
2.11 MundiPharma
2.11.1 MundiPharma Details
2.11.2 MundiPharma Major Business
2.11.3 MundiPharma Non-Hodgkin's Lymphoma Drug Product and Solutions
2.11.4 MundiPharma Non-Hodgkin's Lymphoma Drug Revenue, Gross Margin and Market Share (2019-2024)
2.11.5 MundiPharma Recent Developments and Future Plans
3.1 Global Non-Hodgkin's Lymphoma Drug Revenue and Share by Players (2019-2024)
3.2 Market Share Analysis (2023)
3.2.1 Market Share of Non-Hodgkin's Lymphoma Drug by Company Revenue
3.2.2 Top 3 Non-Hodgkin's Lymphoma Drug Players Market Share in 2023
3.2.3 Top 6 Non-Hodgkin's Lymphoma Drug Players Market Share in 2023
3.3 Non-Hodgkin's Lymphoma Drug Market: Overall Company Footprint Analysis
3.3.1 Non-Hodgkin's Lymphoma Drug Market: Region Footprint
3.3.2 Non-Hodgkin's Lymphoma Drug Market: Company Product Type Footprint
3.3.3 Non-Hodgkin's Lymphoma Drug Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4.1 Global Non-Hodgkin's Lymphoma Drug Consumption Value and Market Share by Type (2019-2024)
4.2 Global Non-Hodgkin's Lymphoma Drug Market Forecast by Type (2025-2030)
5.1 Global Non-Hodgkin's Lymphoma Drug Consumption Value Market Share by Application (2019-2024)
5.2 Global Non-Hodgkin's Lymphoma Drug Market Forecast by Application (2025-2030)
6.1 North America Non-Hodgkin's Lymphoma Drug Consumption Value by Type (2019-2030)
6.2 North America Non-Hodgkin's Lymphoma Drug Consumption Value by Application (2019-2030)
6.3 North America Non-Hodgkin's Lymphoma Drug Market Size by Country
6.3.1 North America Non-Hodgkin's Lymphoma Drug Consumption Value by Country (2019-2030)
6.3.2 United States Non-Hodgkin's Lymphoma Drug Market Size and Forecast (2019-2030)
6.3.3 Canada Non-Hodgkin's Lymphoma Drug Market Size and Forecast (2019-2030)
6.3.4 Mexico Non-Hodgkin's Lymphoma Drug Market Size and Forecast (2019-2030)
7.1 Europe Non-Hodgkin's Lymphoma Drug Consumption Value by Type (2019-2030)
7.2 Europe Non-Hodgkin's Lymphoma Drug Consumption Value by Application (2019-2030)
7.3 Europe Non-Hodgkin's Lymphoma Drug Market Size by Country
7.3.1 Europe Non-Hodgkin's Lymphoma Drug Consumption Value by Country (2019-2030)
7.3.2 Germany Non-Hodgkin's Lymphoma Drug Market Size and Forecast (2019-2030)
7.3.3 France Non-Hodgkin's Lymphoma Drug Market Size and Forecast (2019-2030)
7.3.4 United Kingdom Non-Hodgkin's Lymphoma Drug Market Size and Forecast (2019-2030)
7.3.5 Russia Non-Hodgkin's Lymphoma Drug Market Size and Forecast (2019-2030)
7.3.6 Italy Non-Hodgkin's Lymphoma Drug Market Size and Forecast (2019-2030)
8.1 Asia-Pacific Non-Hodgkin's Lymphoma Drug Consumption Value by Type (2019-2030)
8.2 Asia-Pacific Non-Hodgkin's Lymphoma Drug Consumption Value by Application (2019-2030)
8.3 Asia-Pacific Non-Hodgkin's Lymphoma Drug Market Size by Region
8.3.1 Asia-Pacific Non-Hodgkin's Lymphoma Drug Consumption Value by Region (2019-2030)
8.3.2 China Non-Hodgkin's Lymphoma Drug Market Size and Forecast (2019-2030)
8.3.3 Japan Non-Hodgkin's Lymphoma Drug Market Size and Forecast (2019-2030)
8.3.4 South Korea Non-Hodgkin's Lymphoma Drug Market Size and Forecast (2019-2030)
8.3.5 India Non-Hodgkin's Lymphoma Drug Market Size and Forecast (2019-2030)
8.3.6 Southeast Asia Non-Hodgkin's Lymphoma Drug Market Size and Forecast (2019-2030)
8.3.7 Australia Non-Hodgkin's Lymphoma Drug Market Size and Forecast (2019-2030)
9.1 South America Non-Hodgkin's Lymphoma Drug Consumption Value by Type (2019-2030)
9.2 South America Non-Hodgkin's Lymphoma Drug Consumption Value by Application (2019-2030)
9.3 South America Non-Hodgkin's Lymphoma Drug Market Size by Country
9.3.1 South America Non-Hodgkin's Lymphoma Drug Consumption Value by Country (2019-2030)
9.3.2 Brazil Non-Hodgkin's Lymphoma Drug Market Size and Forecast (2019-2030)
9.3.3 Argentina Non-Hodgkin's Lymphoma Drug Market Size and Forecast (2019-2030)
10.1 Middle East & Africa Non-Hodgkin's Lymphoma Drug Consumption Value by Type (2019-2030)
10.2 Middle East & Africa Non-Hodgkin's Lymphoma Drug Consumption Value by Application (2019-2030)
10.3 Middle East & Africa Non-Hodgkin's Lymphoma Drug Market Size by Country
10.3.1 Middle East & Africa Non-Hodgkin's Lymphoma Drug Consumption Value by Country (2019-2030)
10.3.2 Turkey Non-Hodgkin's Lymphoma Drug Market Size and Forecast (2019-2030)
10.3.3 Saudi Arabia Non-Hodgkin's Lymphoma Drug Market Size and Forecast (2019-2030)
10.3.4 UAE Non-Hodgkin's Lymphoma Drug Market Size and Forecast (2019-2030)
11.1 Non-Hodgkin's Lymphoma Drug Market Drivers
11.2 Non-Hodgkin's Lymphoma Drug Market Restraints
11.3 Non-Hodgkin's Lymphoma Drug Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12.1 Non-Hodgkin's Lymphoma Drug Industry Chain
12.2 Non-Hodgkin's Lymphoma Drug Upstream Analysis
12.3 Non-Hodgkin's Lymphoma Drug Midstream Analysis
12.4 Non-Hodgkin's Lymphoma Drug Downstream Analysis
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Table of Figures
List of Tables
Table 1. Global Non-Hodgkin's Lymphoma Drug Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Table 2. Global Non-Hodgkin's Lymphoma Drug Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Table 3. Global Non-Hodgkin's Lymphoma Drug Consumption Value by Region (2019-2024) & (USD Million)
Table 4. Global Non-Hodgkin's Lymphoma Drug Consumption Value by Region (2025-2030) & (USD Million)
Table 5. Roche Company Information, Head Office, and Major Competitors
Table 6. Roche Major Business
Table 7. Roche Non-Hodgkin's Lymphoma Drug Product and Solutions
Table 8. Roche Non-Hodgkin's Lymphoma Drug Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 9. Roche Recent Developments and Future Plans
Table 10. Gilead Sciences Company Information, Head Office, and Major Competitors
Table 11. Gilead Sciences Major Business
Table 12. Gilead Sciences Non-Hodgkin's Lymphoma Drug Product and Solutions
Table 13. Gilead Sciences Non-Hodgkin's Lymphoma Drug Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 14. Gilead Sciences Recent Developments and Future Plans
Table 15. TG Therapeutics Company Information, Head Office, and Major Competitors
Table 16. TG Therapeutics Major Business
Table 17. TG Therapeutics Non-Hodgkin's Lymphoma Drug Product and Solutions
Table 18. TG Therapeutics Non-Hodgkin's Lymphoma Drug Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 19. TG Therapeutics Recent Developments and Future Plans
Table 20. Bayer Company Information, Head Office, and Major Competitors
Table 21. Bayer Major Business
Table 22. Bayer Non-Hodgkin's Lymphoma Drug Product and Solutions
Table 23. Bayer Non-Hodgkin's Lymphoma Drug Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 24. Bayer Recent Developments and Future Plans
Table 25. Secura Bio Company Information, Head Office, and Major Competitors
Table 26. Secura Bio Major Business
Table 27. Secura Bio Non-Hodgkin's Lymphoma Drug Product and Solutions
Table 28. Secura Bio Non-Hodgkin's Lymphoma Drug Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 29. Secura Bio Recent Developments and Future Plans
Table 30. Epizyme Company Information, Head Office, and Major Competitors
Table 31. Epizyme Major Business
Table 32. Epizyme Non-Hodgkin's Lymphoma Drug Product and Solutions
Table 33. Epizyme Non-Hodgkin's Lymphoma Drug Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 34. Epizyme Recent Developments and Future Plans
Table 35. Eisai Company Information, Head Office, and Major Competitors
Table 36. Eisai Major Business
Table 37. Eisai Non-Hodgkin's Lymphoma Drug Product and Solutions
Table 38. Eisai Non-Hodgkin's Lymphoma Drug Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 39. Eisai Recent Developments and Future Plans
Table 40. Acrotech Biopharma Company Information, Head Office, and Major Competitors
Table 41. Acrotech Biopharma Major Business
Table 42. Acrotech Biopharma Non-Hodgkin's Lymphoma Drug Product and Solutions
Table 43. Acrotech Biopharma Non-Hodgkin's Lymphoma Drug Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 44. Acrotech Biopharma Recent Developments and Future Plans
Table 45. Teva Company Information, Head Office, and Major Competitors
Table 46. Teva Major Business
Table 47. Teva Non-Hodgkin's Lymphoma Drug Product and Solutions
Table 48. Teva Non-Hodgkin's Lymphoma Drug Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 49. Teva Recent Developments and Future Plans
Table 50. Eagle Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 51. Eagle Pharmaceuticals Major Business
Table 52. Eagle Pharmaceuticals Non-Hodgkin's Lymphoma Drug Product and Solutions
Table 53. Eagle Pharmaceuticals Non-Hodgkin's Lymphoma Drug Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 54. Eagle Pharmaceuticals Recent Developments and Future Plans
Table 55. MundiPharma Company Information, Head Office, and Major Competitors
Table 56. MundiPharma Major Business
Table 57. MundiPharma Non-Hodgkin's Lymphoma Drug Product and Solutions
Table 58. MundiPharma Non-Hodgkin's Lymphoma Drug Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 59. MundiPharma Recent Developments and Future Plans
Table 60. Global Non-Hodgkin's Lymphoma Drug Revenue (USD Million) by Players (2019-2024)
Table 61. Global Non-Hodgkin's Lymphoma Drug Revenue Share by Players (2019-2024)
Table 62. Breakdown of Non-Hodgkin's Lymphoma Drug by Company Type (Tier 1, Tier 2, and Tier 3)
Table 63. Market Position of Players in Non-Hodgkin's Lymphoma Drug, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2023
Table 64. Head Office of Key Non-Hodgkin's Lymphoma Drug Players
Table 65. Non-Hodgkin's Lymphoma Drug Market: Company Product Type Footprint
Table 66. Non-Hodgkin's Lymphoma Drug Market: Company Product Application Footprint
Table 67. Non-Hodgkin's Lymphoma Drug New Market Entrants and Barriers to Market Entry
Table 68. Non-Hodgkin's Lymphoma Drug Mergers, Acquisition, Agreements, and Collaborations
Table 69. Global Non-Hodgkin's Lymphoma Drug Consumption Value (USD Million) by Type (2019-2024)
Table 70. Global Non-Hodgkin's Lymphoma Drug Consumption Value Share by Type (2019-2024)
Table 71. Global Non-Hodgkin's Lymphoma Drug Consumption Value Forecast by Type (2025-2030)
Table 72. Global Non-Hodgkin's Lymphoma Drug Consumption Value by Application (2019-2024)
Table 73. Global Non-Hodgkin's Lymphoma Drug Consumption Value Forecast by Application (2025-2030)
Table 74. North America Non-Hodgkin's Lymphoma Drug Consumption Value by Type (2019-2024) & (USD Million)
Table 75. North America Non-Hodgkin's Lymphoma Drug Consumption Value by Type (2025-2030) & (USD Million)
Table 76. North America Non-Hodgkin's Lymphoma Drug Consumption Value by Application (2019-2024) & (USD Million)
Table 77. North America Non-Hodgkin's Lymphoma Drug Consumption Value by Application (2025-2030) & (USD Million)
Table 78. North America Non-Hodgkin's Lymphoma Drug Consumption Value by Country (2019-2024) & (USD Million)
Table 79. North America Non-Hodgkin's Lymphoma Drug Consumption Value by Country (2025-2030) & (USD Million)
Table 80. Europe Non-Hodgkin's Lymphoma Drug Consumption Value by Type (2019-2024) & (USD Million)
Table 81. Europe Non-Hodgkin's Lymphoma Drug Consumption Value by Type (2025-2030) & (USD Million)
Table 82. Europe Non-Hodgkin's Lymphoma Drug Consumption Value by Application (2019-2024) & (USD Million)
Table 83. Europe Non-Hodgkin's Lymphoma Drug Consumption Value by Application (2025-2030) & (USD Million)
Table 84. Europe Non-Hodgkin's Lymphoma Drug Consumption Value by Country (2019-2024) & (USD Million)
Table 85. Europe Non-Hodgkin's Lymphoma Drug Consumption Value by Country (2025-2030) & (USD Million)
Table 86. Asia-Pacific Non-Hodgkin's Lymphoma Drug Consumption Value by Type (2019-2024) & (USD Million)
Table 87. Asia-Pacific Non-Hodgkin's Lymphoma Drug Consumption Value by Type (2025-2030) & (USD Million)
Table 88. Asia-Pacific Non-Hodgkin's Lymphoma Drug Consumption Value by Application (2019-2024) & (USD Million)
Table 89. Asia-Pacific Non-Hodgkin's Lymphoma Drug Consumption Value by Application (2025-2030) & (USD Million)
Table 90. Asia-Pacific Non-Hodgkin's Lymphoma Drug Consumption Value by Region (2019-2024) & (USD Million)
Table 91. Asia-Pacific Non-Hodgkin's Lymphoma Drug Consumption Value by Region (2025-2030) & (USD Million)
Table 92. South America Non-Hodgkin's Lymphoma Drug Consumption Value by Type (2019-2024) & (USD Million)
Table 93. South America Non-Hodgkin's Lymphoma Drug Consumption Value by Type (2025-2030) & (USD Million)
Table 94. South America Non-Hodgkin's Lymphoma Drug Consumption Value by Application (2019-2024) & (USD Million)
Table 95. South America Non-Hodgkin's Lymphoma Drug Consumption Value by Application (2025-2030) & (USD Million)
Table 96. South America Non-Hodgkin's Lymphoma Drug Consumption Value by Country (2019-2024) & (USD Million)
Table 97. South America Non-Hodgkin's Lymphoma Drug Consumption Value by Country (2025-2030) & (USD Million)
Table 98. Middle East & Africa Non-Hodgkin's Lymphoma Drug Consumption Value by Type (2019-2024) & (USD Million)
Table 99. Middle East & Africa Non-Hodgkin's Lymphoma Drug Consumption Value by Type (2025-2030) & (USD Million)
Table 100. Middle East & Africa Non-Hodgkin's Lymphoma Drug Consumption Value by Application (2019-2024) & (USD Million)
Table 101. Middle East & Africa Non-Hodgkin's Lymphoma Drug Consumption Value by Application (2025-2030) & (USD Million)
Table 102. Middle East & Africa Non-Hodgkin's Lymphoma Drug Consumption Value by Country (2019-2024) & (USD Million)
Table 103. Middle East & Africa Non-Hodgkin's Lymphoma Drug Consumption Value by Country (2025-2030) & (USD Million)
Table 104. Non-Hodgkin's Lymphoma Drug Raw Material
Table 105. Key Suppliers of Non-Hodgkin's Lymphoma Drug Raw Materials
List of Figures
Figure 1. Non-Hodgkin's Lymphoma Drug Picture
Figure 2. Global Non-Hodgkin's Lymphoma Drug Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 3. Global Non-Hodgkin's Lymphoma Drug Consumption Value Market Share by Type in 2023
Figure 4. Oral
Figure 5. Injection
Figure 6. Global Non-Hodgkin's Lymphoma Drug Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 7. Non-Hodgkin's Lymphoma Drug Consumption Value Market Share by Application in 2023
Figure 8. Hospital Picture
Figure 9. Retail Pharmacy Picture
Figure 10. Other Picture
Figure 11. Global Non-Hodgkin's Lymphoma Drug Consumption Value, (USD Million): 2019 & 2023 & 2030
Figure 12. Global Non-Hodgkin's Lymphoma Drug Consumption Value and Forecast (2019-2030) & (USD Million)
Figure 13. Global Market Non-Hodgkin's Lymphoma Drug Consumption Value (USD Million) Comparison by Region (2019 & 2023 & 2030)
Figure 14. Global Non-Hodgkin's Lymphoma Drug Consumption Value Market Share by Region (2019-2030)
Figure 15. Global Non-Hodgkin's Lymphoma Drug Consumption Value Market Share by Region in 2023
Figure 16. North America Non-Hodgkin's Lymphoma Drug Consumption Value (2019-2030) & (USD Million)
Figure 17. Europe Non-Hodgkin's Lymphoma Drug Consumption Value (2019-2030) & (USD Million)
Figure 18. Asia-Pacific Non-Hodgkin's Lymphoma Drug Consumption Value (2019-2030) & (USD Million)
Figure 19. South America Non-Hodgkin's Lymphoma Drug Consumption Value (2019-2030) & (USD Million)
Figure 20. Middle East and Africa Non-Hodgkin's Lymphoma Drug Consumption Value (2019-2030) & (USD Million)
Figure 21. Global Non-Hodgkin's Lymphoma Drug Revenue Share by Players in 2023
Figure 22. Non-Hodgkin's Lymphoma Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2023
Figure 23. Global Top 3 Players Non-Hodgkin's Lymphoma Drug Market Share in 2023
Figure 24. Global Top 6 Players Non-Hodgkin's Lymphoma Drug Market Share in 2023
Figure 25. Global Non-Hodgkin's Lymphoma Drug Consumption Value Share by Type (2019-2024)
Figure 26. Global Non-Hodgkin's Lymphoma Drug Market Share Forecast by Type (2025-2030)
Figure 27. Global Non-Hodgkin's Lymphoma Drug Consumption Value Share by Application (2019-2024)
Figure 28. Global Non-Hodgkin's Lymphoma Drug Market Share Forecast by Application (2025-2030)
Figure 29. North America Non-Hodgkin's Lymphoma Drug Consumption Value Market Share by Type (2019-2030)
Figure 30. North America Non-Hodgkin's Lymphoma Drug Consumption Value Market Share by Application (2019-2030)
Figure 31. North America Non-Hodgkin's Lymphoma Drug Consumption Value Market Share by Country (2019-2030)
Figure 32. United States Non-Hodgkin's Lymphoma Drug Consumption Value (2019-2030) & (USD Million)
Figure 33. Canada Non-Hodgkin's Lymphoma Drug Consumption Value (2019-2030) & (USD Million)
Figure 34. Mexico Non-Hodgkin's Lymphoma Drug Consumption Value (2019-2030) & (USD Million)
Figure 35. Europe Non-Hodgkin's Lymphoma Drug Consumption Value Market Share by Type (2019-2030)
Figure 36. Europe Non-Hodgkin's Lymphoma Drug Consumption Value Market Share by Application (2019-2030)
Figure 37. Europe Non-Hodgkin's Lymphoma Drug Consumption Value Market Share by Country (2019-2030)
Figure 38. Germany Non-Hodgkin's Lymphoma Drug Consumption Value (2019-2030) & (USD Million)
Figure 39. France Non-Hodgkin's Lymphoma Drug Consumption Value (2019-2030) & (USD Million)
Figure 40. United Kingdom Non-Hodgkin's Lymphoma Drug Consumption Value (2019-2030) & (USD Million)
Figure 41. Russia Non-Hodgkin's Lymphoma Drug Consumption Value (2019-2030) & (USD Million)
Figure 42. Italy Non-Hodgkin's Lymphoma Drug Consumption Value (2019-2030) & (USD Million)
Figure 43. Asia-Pacific Non-Hodgkin's Lymphoma Drug Consumption Value Market Share by Type (2019-2030)
Figure 44. Asia-Pacific Non-Hodgkin's Lymphoma Drug Consumption Value Market Share by Application (2019-2030)
Figure 45. Asia-Pacific Non-Hodgkin's Lymphoma Drug Consumption Value Market Share by Region (2019-2030)
Figure 46. China Non-Hodgkin's Lymphoma Drug Consumption Value (2019-2030) & (USD Million)
Figure 47. Japan Non-Hodgkin's Lymphoma Drug Consumption Value (2019-2030) & (USD Million)
Figure 48. South Korea Non-Hodgkin's Lymphoma Drug Consumption Value (2019-2030) & (USD Million)
Figure 49. India Non-Hodgkin's Lymphoma Drug Consumption Value (2019-2030) & (USD Million)
Figure 50. Southeast Asia Non-Hodgkin's Lymphoma Drug Consumption Value (2019-2030) & (USD Million)
Figure 51. Australia Non-Hodgkin's Lymphoma Drug Consumption Value (2019-2030) & (USD Million)
Figure 52. South America Non-Hodgkin's Lymphoma Drug Consumption Value Market Share by Type (2019-2030)
Figure 53. South America Non-Hodgkin's Lymphoma Drug Consumption Value Market Share by Application (2019-2030)
Figure 54. South America Non-Hodgkin's Lymphoma Drug Consumption Value Market Share by Country (2019-2030)
Figure 55. Brazil Non-Hodgkin's Lymphoma Drug Consumption Value (2019-2030) & (USD Million)
Figure 56. Argentina Non-Hodgkin's Lymphoma Drug Consumption Value (2019-2030) & (USD Million)
Figure 57. Middle East and Africa Non-Hodgkin's Lymphoma Drug Consumption Value Market Share by Type (2019-2030)
Figure 58. Middle East and Africa Non-Hodgkin's Lymphoma Drug Consumption Value Market Share by Application (2019-2030)
Figure 59. Middle East and Africa Non-Hodgkin's Lymphoma Drug Consumption Value Market Share by Country (2019-2030)
Figure 60. Turkey Non-Hodgkin's Lymphoma Drug Consumption Value (2019-2030) & (USD Million)
Figure 61. Saudi Arabia Non-Hodgkin's Lymphoma Drug Consumption Value (2019-2030) & (USD Million)
Figure 62. UAE Non-Hodgkin's Lymphoma Drug Consumption Value (2019-2030) & (USD Million)
Figure 63. Non-Hodgkin's Lymphoma Drug Market Drivers
Figure 64. Non-Hodgkin's Lymphoma Drug Market Restraints
Figure 65. Non-Hodgkin's Lymphoma Drug Market Trends
Figure 66. Porters Five Forces Analysis
Figure 67. Manufacturing Cost Structure Analysis of Non-Hodgkin's Lymphoma Drug in 2023
Figure 68. Manufacturing Process Analysis of Non-Hodgkin's Lymphoma Drug
Figure 69. Non-Hodgkin's Lymphoma Drug Industrial Chain
Figure 70. Methodology
Figure 71. Research Process and Data Source
Research Methodology
Client Requirements
Review and analyze client requirements
Discussion of all the project requirements and queries
Flexibility Check
Project Feasibility Analysis
Finalizing tentative research programme
Structuring project proposal with scope, timeline, and costs
Analyzing Market Dynamics
Determination of key drivers, restraints, challenge, and opportunity
Identifies market needs and trends
Market Size Estimation & Forecast
Estimation of historical data based on secondary and primary data
Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)
Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies
Consideration of geography, region-specific product/service demand for region segments
Consideration of product utilization rates, product demand outlook for segments by application or end-user.
Data Source
Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports,
paid database, press releases, blogs, newsletters,and GIR repositories.
Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts
to verify insights.
Validation
and
triangulation of
secondary and primary source.
Collection of data
Cumulating and collating the essential qualitative and quantitative data
Generation of report in client requested format by research analysts
Reviews by expert analysts
Final quality check
Clarifying queries
Receiving feedback
Ensuring satisfaction
01 Identification of data
This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
-
02 Evaluation of Market Dynamic
This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
-
03 Collection of Data
This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
-
04 Collaboration of Data
This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis
This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.
Companies Mentioned
Roche Gilead Sciences TG Therapeutics Bayer Secura Bio Epizyme Eisai Acrotech Biopharma Teva Eagle Pharmaceuticals MundiPharma
Related Reports
09 Jan 2023
Pharma & Healthcare
Purchase Options
Add To Cart
Buy Now
Popular Product Keywords
- We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.Speak to our analyst >>
Our Clients
What We Can Provide?
With better results and higher quality products,Our professional reports can achieve four things:
Insight into the industry market information
Analyze market development needs
Prospects for future development
Develop industry investment strategy
- Digging deeper into global industry information and providing market strategies.Contact Us >>
